In-Person and By Zoom
Zoom ID: 979 6297 5142
Contact corit@hawaii.edu for passcode
Asmita Pandey
Ph.D. Student
Department of Tropical Medicine, Medical Microbiology and Pharmacology
John A. Burns School of Medicine
University of Hawaii at Manoa
Non-small cell lung cancer (NSCLC) has a poor survival rate due to delayed diagnosis and treatment resistance. Immunotherapies have advanced the NSCLC treatment at present, however, only a small fraction of patients respond to the therapy, which necessitates to identify biomarkers that play a role in therapy resistance. From the list of anti-PD1/PD-L1 treatment resistance-associated biomarkers, identified by studies done in our lab, we discovered that Neogenin 1 (Neo1) shows relatively high expression in the NSCLC patients that leads to increased resistance. We hypothesized that high expression of Neo1 in NSCLC patients downregulates PD1/PD-L1 expression leading to the treatment resistance. To validate this, we plan to perform Neo1 manipulation in NSCLC and jurkat T cells to measure the effect on PD1/PD-L1 expression, following the investigation of the anti-PD1/PD-L1 treatment response in co-culture environment. In future, our goal is to explore the mechanism on how Neo1 overexpression regulates PD1/PD-L1 expression.